glp 1 best practices Curious about GLP-1 medications? They can help with weight management, but are there side effects you should be aware of? Tap to read more! Link in Bio #Health #Diabetes #Wellness #medicalweightloss Weighing in on GLP-1 Dining

Description

doi: 10.1111/bcpt.13169

Why 2026 could be a big year for GLP-1s The next wave of obesity medications isnt just more GLP-1. Many candidates are designed to improve results by combining GLP-1 with other hormone pathways that influence: Appetite and satiety signaling in the brain Gastric emptying and cravings Energy expenditure and fat metabolism Insulin sensitivity and cardiometabolic risk factors That means the future may include: Oral (pill) GLP-1 therapy for weight management Combination therapies that intensify satiety (like amylin-based add-ons) Multi-agonist incretins (triple-hormone approaches) 1) Orforglipron (oral GLP-1 pill) a likely 2026 headliner What it is: Orforglipron is an oral, small-molecule GLP-1 receptor agonist being developed by Eli Lilly for obesity and type 2 diabetes

10.1111/dom.12506

Its a great example of how our large-scale, participant-engaged research program can clarify the biological mechanisms behind drug response, and moves us closer to a future where precision medicine isnt just an aspiration. Translating Emerging Science into Personalized Insights Discovering these variants is a massive step forward, but our ultimate goal is to meet the need for more personalized insight into GLP-1 medication responses